N🟁N

Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2009

  //health-fitness.news-articles.net/content/2009/ .. ent-at-the-bio-ceo-investor-conference-2009.html
  Published in Health and Fitness on Thursday, January 29th 2009 at 5:54 GMT, Last Modified on 2009-01-29 05:54:56 by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

LEXINGTON, Mass.--([ BUSINESS WIRE ])--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the BIO CEO & Investor Conference on Monday, February 9, 2009 at 3:15 pm (ET) at the Waldorf Astoria Hotel in New York.

In addition, Safi Bahcall, Ph.D., President and CEO, Synta Pharmaceuticals will be a panelist in the BIO CEO therapeutic workshop Oncology: The Forecast for the Melanoma Market—Partly Sunny or Mostly Cloudy? at 12:30 pm (ET) on Tuesday, February 10. Dr. Bahcall will discuss oxidative stress induction as a new therapeutic approach to treating melanoma and other cancers.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, [ www.syntapharma.com ]. The panel will not be webcast.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit [ www.syntapharma.com ].